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Abstract: This paper discusses the need for interconnecting computational cancer models from different sources and scales within 
clinically relevant scenarios to increase the accuracy of the models and speed up their clinical adaptation, validation, and eventual 
translation. We briefly review current interoperability efforts drawing upon our experiences with the development of in silico models for 
predictive oncology within a number of European Commission Virtual Physiological Human initiative projects on cancer. A clinically 
relevant scenario, addressing brain tumor modeling that illustrates the need for coupling models from different sources and levels of 
complexity, is described. General approaches to enabling interoperability using XML-based markup languages for biological modeling 
are reviewed, concluding with a discussion on efforts towards developing cancer-specific XML markup to couple multiple component 
models for predictive in silico oncology.
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Introduction
The last few decades have witnessed an increased 
interest of the scientific community in the development 
of computational models for simulating tumor growth 
and response to treatment.1–8 The major modeling 
techniques can be differentiated as predominantly 
continuous and predominantly discrete models. 
Continuous models rely primarily on differential 
equations to describe processes such as diffusion of 
molecules, changes in tumor cell density, and invasion 
of tumor cells into the surrounding tissue.9–14 Discrete 
modeling considers several discrete states in which 
cells may be found and possible transitions between 
them governed by “decision calculators” such as 
cytokinetic diagrams and agent-based techniques.15–20 
Discrete models are usually represented by cellular 
automata of several forms and variable complexity. 
Due to the hypercomplexity21 of cancer-related 
topics, each modeling approach is intrinsically able 
to satisfactorily address only some of the aspects of 
this multifaceted problem.
In recent years, data-driven computational 
cancer modeling has become an active field 
in cancer research.22 In particular, the development 
of cancer models that encompass different biological 
scales in time and space (ie, multiscale cancer models) 
has gained attention in view of the potential to integrate 
disparate kinds of patient data and to enable patient-
specific prediction and assist in treatment planning.23–25 
Consequently, these techniques fall into two basic 
types of approaches to cancer modeling: “bottom-up” 
and “top-down.” The bottom-up approach studies the 
components of a system individually and then integrates 
the properties and functions of each component to make 
predictions about the behavior of the entire system.26 
On the other hand, a top-down approach, driven by 
observed biological characteristics or phenomena, 
builds up theories that would explain the observed 
behavior.26 In the particular case of cancer simulation 
and prediction, agent-based modeling (ABM) has 
been widely adopted as a useful technique for 
developing bottom-up models, whereas both discrete 
and continuum modeling are used for developing top-
down models. Combining both techniques yields a 
“hybrid” approach.
The bottom-up approach is suitable for simulating 
emergent cancer behaviors resulting from cell-cell 
and cell-host interactions and intracellular signaling 
of individual cells. Many bottom-up multiscale cancer 
models have been developed so far where most of 
them are based on the ABM technique and incorporate 
a specific molecular-level description. Recent 
representative examples include those quantifying 
the relationship between extracellular growth factors 
and multicellular cancer growth and expansion,27–30 
those investigating cancer cell motility in an evolving 
tumor population by connecting gene regulatory 
networks to cell phenotypes,31–33 those describing 
genotype-phenotype relations based on and studying 
the effects of different cell adhesion pathways on 
cancer cell invasion patterns.34,35 All these models 
explicitly access and draw on prior knowledge about 
biochemical and biophysical mechanisms and the 
underlying biological properties of cancer. This 
demonstrates the potential of the bottom-up approach 
in making full use of the sizeable amount of molecular 
and microscopic data being generated experimentally 
and in clinics. A top-down simulation approach15,36,37 
typically starts from the macroscopic imaging data 
(a high biocomplexity level) and proceeds toward 
lower biocomplexity levels. When there is a need for 
an upward movement in the biocomplexity scales, 
a summary of the available information pertaining 
to the previous lower level is used. A top-down 
approach is suitable for directly simulating clinical 
trials, and therefore clinically adapting, validating, 
and eventually translating the models into clinical 
practice. It also offers the possibility to exploit the 
actual multiscale data of the individual patient, 
including molecular markers.
To better understand and subsequently treat cancer 
more effectively, a significant effort is underway to 
develop and use models of cancer pathophysiology 
in order to simulate cancer evolution and promote 
individualized, that is, patient-specific optimization 
of, disease treatment. The latter is leading to a central 
clinical question from the context of predictive 
oncology: Is it possible to select the best targeted 
therapy for a patient by computer simulation?
To answer this question and be able to promote 
predictive oncology, it is mandatory to validate cancer 
models in real clinical cases and assess the added value 
in optimizing therapy selection for the individual 
patient in studies. It is important to keep in mind that 
cancer is a multiscale phenomenon, and while many 
research groups develop significant models, they 
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usually address only specific scales (from molecular 
to tissue level) and are difficult to integrate due to the 
fact that there is no universally accepted standard for 
presenting and implementing such models. Another 
adverse effect of such compartmentalized research is 
that there is no established protocol for the clinical 
validation of cancer models or for the assessment of 
their results. In particular, the lack of standardized 
descriptions of models significantly hampers their 
widespread adoption and clinical testing and, more 
importantly, their interconnection in order to efficiently 
couple models of different scales and improve their 
accuracy.
This paper draws on our experiences with the VPH38 
(Virtual Physiological Human, http://www.vph-noe.
eu) projects on cancer modeling: ACGT39 (Advancing 
Clinico Genomic Trials on Cancer, eu-acgt.org), 
ContraCancrum6 (Clinically Oriented Cancer 
Multilevel modelling, http://www.contracancrum.eu) 
and the US CViT40 (Center for the Development of a 
Virtual Tumor, http://www.cvit.org) projects. We also 
look to the future with the developments within the 
TUMOR41 (Transatlantic Tumor Model Repositories, 
http://www.tumour-project.eu) project that is paving 
the way for an integrated, interoperable transatlantic 
research environment and investigating standards 
for simulation and modeling within the domain of 
predictive in silico oncology.
clinically Oriented in silico Oncology
Sophisticated multiscale models yield valuable 
quantitative insights into complex mechanisms 
involved in cancer and may ultimately contribute to 
patient-specific therapy optimization. The ultimate 
goal of clinically oriented cancer simulation models is 
their eventual translation into clinical practice, which 
entails two key steps. Firstly, thorough sensitivity 
analyses are carried out in order to both comprehend 
and validate model behaviors. This will enable 
researchers to gain further insights into the simulated 
mechanisms in a more quantitative way. Secondly, 
an adaptation and validation process based on real 
clinical data is carried out.
The clinical orientation of a model constitutes 
a fundamental guiding principle throughout its 
development. In order to ultimately support clinical 
decision making in a patient-individualized manner, 
clinically oriented models should be under continuous 
refinement within the framework of clinical trials. For 
a clinician it is important that the in silico experiments 
can address and answer precisely for each patient the 
following questions: What is the natural course of the 
tumor growth over time in size and shape? When and 
where to is the tumor metastasizing? Can the response 
of the local tumor and the metastases to a given 
treatment be predicted in size and shape over time? 
What is the best treatment schedule in terms of drugs, 
surgery, irradiation, and their combination, dosage, 
time schedule and duration to achieve a positive 
outcome? Is it possible to predict severe adverse 
events of a treatment and to propose alternatives to 
them without jeopardizing the outcome? Is it possible 
to predict a cancer before it occurs and to recommend 
treatment options to prevent the occurrence or a 
recurrence? The question to be addressed would be 
decided by the clinician and consequently influence 
the model. Clinically oriented in silico oncology 
seeks to address such questions.
An example clinical scenario
To exemplify the need for coupling models together 
for clinically-oriented in silico oncology, in this 
section we describe a clinical scenario that combines 
two distinctly different approaches for different 
purposes to increase the accuracy of a diagnosis.
Malignant gliomas (World Health Organization 
[WHO] grade III and IV) are progressive brain tumors 
that can be divided into anaplastic gliomas (WHO 
grade III) and glioblastoma multiforme (GBM) 
(WHO grade IV) based upon their histopathologic 
features.42,43 Magnetic resonance imaging (MRI) has 
become the method of choice in the diagnostic workup 
of these patients.44 Because of edema surrounding 
the tumor and the presence of necrotic and vital 
areas within the tumor, the exact tumor volume is 
nearly impossible to define.45 This is true at the time 
of diagnosis and even much more enhanced during 
treatment, as edema and necrotic areas might change 
with an increase in tumor volume despite treatment 
response (pseudoprogression).
Magnetic resonance spectroscopy, diffusion 
weighted imaging, as well as perfusion MRI, can 
depict changes in the cellular metabolism. Positron 
emission tomography is used to detect tumors with 
high metabolic rates of glucose. These commonly 
used imaging modalities still pose problems when 
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identifying pseudoprogression and pseudoregression 
in clinical practice. On average, patients who suffer 
from grade III gliomas have an average survival of 
2 to 3 years. In contrast, most patients with GBM die of 
the disease within a year following diagnosis.42,46 Over 
the last few years the most important improvement 
has been achieved by the concomitant and adjuvant 
application of temozolomide and radiotherapy, which 
increased the survival period from approximately 
12 to 15 months.47 Long-term survivors for more 
than 5 years are sparse (3%–5% of GBM patients).48 
Improvement in outcome of patients with GBM is 
urgently needed and can only be achieved through a 
combined effort between clinicians, basic researchers, 
computer scientists, mathematicians, and legal and 
ethical policy-makers. New treatment modalities 
need to be developed.
The simulation of GBM in silico is one such 
option by modeling tumor growth and response to 
treatment. Since cancer is a strongly multiscale natural 
phenomenon, in order to be able to provide 
reliable predictions of its spatiotemporal course, 
including response to treatment modalities, several 
biocomplexity scales should be addressed concurrently 
in a combinatorial way. This implies that sufficiently 
advanced models of several biomechanisms 
concerning different spatiotemporal scales have to 
be developed and adequately coupled. Different 
modeling groups worldwide focus on different scales 
and contexts of tumor dynamics. Therefore, the 
models they produce have in general different external 
and internal structures. Coupling such models tends 
to be a highly demanding task. The combination of a 
bottom-up approach with a top-down approach will 
combine data from systems biology such as cell cycle 
duration or methylation status of MGMT (a DNA repair 
gene correlating with outcome after temozolomide 
treatment49) or deregulated metabolic pathways with 
real patient data such as age, appearance of the tumor 
in imaging studies, and outcome. As a goal for the 
future, such spatiotemporal multidimensional models 
have to be integrated into daily clinical care and need 
to provide validated results for single patients in due 
time. Clinicians using such models should be guided 
by a closed workflow that encapsulates patient data 
provision, preprocessing and postprocessing of data 
(including anonymization or pseudonymization of 
patient-identifiable data), uploading and integration 
of data, and computational execution of the chosen 
in silico model. The validated results after model 
execution are then sent to the clinician to assist 
in the treatment decision-making process. For 
example, consider the following possible models of 
treatment response in GBM that may be calculated 
computationally: (1) Differentiation between real 
progression and pseudoprogression after irradiation 
of the tumor and (2) Simulation of the response 
to a combined treatment with irradiation and 
temozolomide.
The correct assessment of response to a given 
treatment is difficult to assess. An unspecific 
disruption of the blood-brain barrier may cause a 
reactive treatment-related edema mimicking tumor 
progression.44 This is often seen after irradiation 
and summarized as pseudoprogression. On the other 
hand, pseudoregression is also found if treatment 
(eg, antiangiogenic drugs) is not affecting the tumor 
itself but the surrounding edema.50 While a predictive 
simulation of treatment response in the second 
model provides a means to assisting therapy, the 
differentiation of real and pseudo responses, as in the 
first model, could be integrated. These two models 
coupled together might increase the accuracy of an in 
silico prediction of GBM treatment response.51
An Overview of Major 
Interoperability efforts
The need for coupling models together has been 
highlighted by the clinical scenario described in the 
previous section, but how can we facilitate connecting 
disparate models together? Markup languages for 
modeling biological systems (based on the Extensible 
Markup Language [XML]52,53) emerged in the early 
2000s to address the problems associated with the 
lack of standards for describing biological models. 
Four major languages have gained prominence 
in recent years each of which aims to tackle the 
problems associated with interoperability of models. 
The markup languages discussed here are SBML, 
CellML, FieldML and insilicoML.
Systems biology markup language
The Systems Biology Markup Language, commonly 
referred to as SBML, is a domain-specific markup 
language that addresses biochemical processes 
at the molecular scale.54,55 The motivations for 
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SBML were 3-fold: (1) to support multiple tools 
with a single common file format, (2) to enable 
repeatability of experiments with published models 
irrespective of modeling software platform, and 
(3) to promote longevity of published models beyond 
the lifetime of current modeling tools. These aims 
are quite generalized; however, the authors explain 
that SBML does not aim to be a generic modeling 
language to cover all types of quantitative models. 
They recognize that the de facto understanding of 
different biological concepts evolve, and, as such, they 
submit that a modeling language for systems biology 
be domain-specific and is structured to represent the 
consensus of current understanding in the field. This 
aims to enable the state-of-the-art modeling tools in 
systems biology to use a common language in which 
to communicate models rather than having a single 
generic modeling language for biological and/or 
computational modeling.
To describe the mathematical components in SBML, 
the language utilizes Content MathML, an XML 
language for describing mathematical formulae.56 
Typically, the mathematics used to model systems 
biology is in the form of declarative formulae such 
as ordinary differential equations (ODEs) and partial 
differential equations (PDEs), and the markup used 
can adequately describe such equations. Models are 
structured as sets of components termed compartments 
that broadly represent containers for chemical 
substances. Changes in the values and states within 
compartments are dictated by description statements 
of biochemical transformations or transport. It also 
provides the facility to associate metadata with 
models in order to properly curate them within online 
databases. The details of the latest release of SBML 
(Level 3) are extensively described in Hucka et al.55
CellmL
Developed out of the physiological modeling 
community, CellML is a modeling markup language 
that aims to cover a range of biological phenomenon, 
primarily cell function.57,58 CellML was developed to 
address the lack of standards for describing cellular 
function and to provide unambiguous representations 
of models. The authors identified that because of the 
lack of rigor and standards in the publishing process, 
models could not be easily validated. Errors are 
commonly introduced when publishing models in 
journal texts, and computational implementations are 
commonly targeted at specific software frameworks 
and tools, making the models themselves less portable. 
This poses problems when sharing with researchers 
who are unfamiliar with the modeling methodologies, 
frameworks, and tools others may have used.
Like SBML, CellML utilizes Content MathML 
to describe systems modeled using mathematical 
equations. CellML is designed to be modular in that 
encapsulated models (possibly of different scales) 
can be linked together through public and private 
interfaces. This allows multiple models whose 
variables might refer to the same entity can be logically 
linked. This component-based approach allows reuse 
of whole models or parts of models described with 
CellML markup. To compliment CellML’s functional 
description of biological cells, FieldML is being 
developed as a language for modeling physiological 
structures based on geometric meshes and fields, 
allowing the representation of spatial variation and 
PDEs.59 Structures are represented as abstractions 
of physical states over locations described and 
approximated sets of functions.
insilicomL
insilicoML (ISML) is a markup language for describing 
biological models developed out of the Japanese 
Physiome Project.60–62 ISML was developed to be 
a modular description of models and has a number 
of similarities to CellML. The authors designed the 
language with a set of tools that facilitate conversion 
to multiple representational formats such as CellML, 
SBML, general-purpose source code (C++), and 
document markup (LaTeX). ISML supports a range 
of mathematical models such as those described with 
ODEs and PDEs as well as ABM-based models that 
utilize descriptions of conditional behavior.
ISML models a system as an aggregate set 
of modules corresponding to entities each with 
a state and corresponding implementation. The 
implementation details how the states change in 
reaction to specific events and to the progression of 
time and, like CellML and SBML, can be modeled 
mathematically. Graph-like edges linking input/
output nodes of modules, termed ports, are used for 
signaling and communication between modules. 
These edges enable the communication of physical 
quantities representing different values of a module’s 
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internal state. By structuring biological models in this 
way, models can be constructed from components as 
graphs and hierarchies and represented as independent 
modules. Modules in ISML are conceptualized 
as capsules (the authors term this “capsulation”). 
Calpsulation is where multiple capsules are grouped 
and linked together, packaging them into a larger 
capsule module. Capsules, like other modules, also 
possess input and output ports to allow aggregates 
to be composed of other aggregates. To create 
logical connections between capsules ports with 
the encapsulated internal modules, a special case of 
edge, termed a “forwarding edge,” links capsule ports 
with internal module ports. Capsulation can lead to 
the composition of hierarchical representations of 
models.
A number of similarities exist between ISML 
and CellML. For example, the concepts of ISML 
modules and physical quantities map to CellML’s 
components and variables respectively. However, 
these parallels are not exhaustive. Although CellML 
connections between public and private model 
interfaces are structurally similar to ISML’s edges 
and ports, respectively, in CellML connections link 
entity variables that are semantically equivalent but 
do not model any directionality. ISML edges have 
explicit direction from input ports to output ports. 
Additionally, ISML edges can have operational types 
attached to them by labeling each edge with a verb or 
verb phrase describing a functional relationship. ISML 
modules also have a defined type such as functional 
unit, container, capsule, or template. The definitions 
of each ISML module type are not discussed in this 
paper but are described in full in a series of papers by 
the original authors.60–62
Discussion
Each of the markup languages reviewed approaches 
modeling different aspects of biology in a generalized 
fashion. However, we do not believe that such 
a generic approach to modeling is appropriate 
when considering more complex, wide-ranging 
phenomenon and multiscale behaviors considered in 
the current cancer modeling literature. Typically, these 
state-of-the-art markup languages take a declarative 
mathematical approach to modeling, where the 
biological simulations are derived by mathematical 
formulae being fed into numerical solvers. They all 
use MathML for functional and behavioral description, 
and, while MathML is a mature markup language, 
it does not provide any constructs for describing 
logic and control flow or complex data structures. 
Models based on markup using MathML are typically 
simulated through solving ODEs and differential 
algebraic equations. Control flow constructs and 
domain-specific components will give a biological 
modeling markup language more expressive power, 
especially where models are developed using an in 
silico methodology rather than a purely declarative 
mathematical approach.63 For example, algorithmic 
and cellular automata-based cancer models cannot be 
expressed in any of the currently available markup 
languages, let alone any hybrid top-down–bottom-up 
composite models.
The generic application target of these markup 
languages is also a barrier to their adoption and 
usage for cancer modeling. SBML is a specialized 
language that describes molecular components and 
their relationships with each other. CellML expresses 
models as declarative mathematics that is processed 
by numerical solvers, mainly to model cell function, 
and the domain concepts in CellML are decoupled 
from the language as metadata annotations. FieldML 
adds the spatial description element to compliment 
CellML models, but it is however limited to continuous 
models of behaviour, being unable to represent the 
discrete ABM approaches. ISML is similar to CellML 
in its application to a wide range of biology, and also 
demonstrates multiscale application, but again in a 
very generic fashion.
SBML Level 3 supports modular linking of models 
through hierarchical model composition. A model 
definition might contain several submodel instances 
each as part of a composite model. “Ports” are used to 
act as interfaces to internal elements of a SBML model; 
however, these are optional. In practice, submodels 
declared with model definitions embedded within the 
same document allow direct access to other submodel 
internal details. Although the use of ports was 
introduced to define abstract interfaces, they do not 
enforce any sort of encapsulation ultimately leading 
to content coupling. CellML version 1.1 is designed 
to be modular in that encapsulated models can be 
linked together through public and private interfaces. 
This allows multiple models whose variables might 
refer to the same entity to be logically linked. 
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This component-based approach allows reuse of 
whole models or parts of models described with 
CellML markup. This modular coupling has been 
demonstrated in a number of published models; 
however, it is not without its problems. Variables can 
be made directly accessible by declaring them to be so 
through public interfaces leading to content coupling. 
Both SBML and CellML encapsulate models and 
internal components to a certain degree, but their 
approaches look to relatively basic solutions to 
ensure backwards compatibility for existing models. 
What neither language takes into account is that by 
simply allowing direct connectivity of data between 
modules, any notion of cohesion is not accounted for. 
Models typically simulate multiple processes where 
biological concepts may be spread over different 
parts of the code or multiple concepts represented in 
one portion of code. A smarter approach to grouping 
concerns is needed to achieve true modularity and 
encapsulation.
To address the specific domain of cancer modeling, 
we are actively involved with the development 
of a markup language, TumorML, to describe 
computational models within the TUMOR project. 
The motivation for such a markup language is 2-fold: 
(1) to describe the implementation of these cancer 
models in an abstract manner that is not tied to any 
particular programming notation and (2) to be able 
to couple our models64 to address cases such as the 
GBM scenario described earlier. The challenges 
posed in developing TumorML include formalizing 
cancer terminology, linking biological entities with 
computational and mathematical elements of models, 
and incorporating features to allow for curating 
models in online repositories.
Initially we have developed a vocabulary that 
includes metadata for curation (reusing the Dublin 
Core Metadata Element Set (http://www.dublincore.
org) combined with our own cancer-specific metadata) 
and for describing the public interfaces with existing 
models that have been developed and published as 
source code and executable files, the groundwork 
of which has been described by Johnson et al.65 This 
will allow us to investigate how to couple models 
of different scales together through their exposed 
parametric inputs and outputs; an initial “black box” 
approach to computational model execution and 
coupling. Portions of the Job Description Markup 
Language66 are reused to facilitate the specification 
of the underlying computational requirements 
for executing computational models. Parametric 
interfaces are described as named variables with 
unit and quantity metadata annotations. These 
computational interfaces could then be mapped to 
biological terminology ultimately providing a way 
to more easily validate the cancer biology through 
correct semantic matching, but also to provide a 
means to enforce type and units checking where 
heterogeneities in model descriptions exist.
Domain-specific markup, such as TumorML, could 
be used to assist in the coupling models of different 
scales that may have very distinct concerns. If we 
consider our earlier GBM scenario, our first model 
is solely concerned with differentiating between real 
and pseudo progression and regression of a tumor 
after radiotherapy. This might be calculated by 
analyzing a patient’s MRI scans at the macroscopic 
scale. Our second model concerns simulation of 
predicted tumor growth after a combination of 
therapies, perhaps looking at cell-cell interactions 
in tissue at the microscopic scale based on a wide 
range of patient data in combination with initial MRI 
scans. Treating model implementations as black 
boxes, exposed only through a declared interface, 
in combination with metadata relating to how to 
run a model, may allow compound models to be 
constructed via markup.
The cancer modeling community is adopting 
TumorML for publishing existing models, beginning 
with efforts in TUMOR and related projects, and we 
are working with modelers to develop the next level 
of more detailed abstractions of the inner workings 
of models, such as work on embedding functional 
domain-specific code (for vascular tumor growth) 
into TumorML documents.67 Significant effort might 
be required to port existing models to TumorML, so 
by providing multiple levels of abstractive notation 
in our markup we can wrap existing models in 
early versions of TumorML as well as develop new 
models with an evolving markup specification. 
Experimental and clinically oriented vocabularies 
or ontologies, such as the Simulation Experiment 
Description Markup Language (SED-ML)68 and 
the CancerGrid model ontology,69 could also be 
integrated to assist in management of clinical trials 
of TumorML models.
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conclusion
Predictive in silico oncology is an evolving field of 
study, and, with an increasing number of models 
being developed by a growing research community, 
standards need to be adopted to facilitate model sharing 
and interoperability. Modeling cancer is approached 
from two distinct angles: bottom-up, from a finer-level 
molecular modeling detail to simulate higher-level 
observed behaviors, and top-down, where models are 
actually based on macroscopic observed behavior. The 
two types of techniques can be combined to possibly 
increase the accuracy of clinically relevant models 
such as those exploited by the VPH projects (ACGT, 
ContraCancrum) and CViT. An ability to couple 
models of different scales and approaches is needed, 
as illustrated by the GBM scenario described in this 
paper, where the combination of models to differentiate 
between real progression and pseudoprogression in 
response to treatment and the simulation of tumor 
growth with and without treatment is just one possible 
example of how one might increase the accuracy of 
using such computational cancer models in predictive 
oncology. The currently available markup languages 
reviewed each have their own merits; however, each 
also has its own pitfalls when applied to the cancer-
modeling domain. SBML is specific to the domain of 
systems biology, FieldML, to physiological structures, 
while CellML and ISML are too generalized and 
lack the domain-specific descriptive power required 
in cancer modeling. TumorML is being developed to 
address the need for a standardized domain-specific 
multiscale cancer markup language, where the existing 
state-of-the-art alternatives fall short. The combination 
of existing cancer ontologies with existing markup 
vocabularies will lead to the facilitation of model 
coupling, ultimately leading to the possibility of better, 
more accurate in silico models that move one step closer 
to clinical translation and use in predictive oncology.
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